The Global Market for Prophylactic Human Vaccines is Projected to Reach US$50.1 Billion by 2022

Growing Importance of Vaccines in Public Health & in Ensuing Sustainability of the Healthcare System Drives the Prophylactic Human Vaccines Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Prophylactic Human Vaccines market. The global market for Prophylactic Human Vaccines is projected to reach US$50.1 billion by 2022, driven by the growing importance of vaccines in safeguarding public health, reducing healthcare costs and contributing towards a more sustainable healthcare system.    

Vaccines represent biological preparations that offer immunity to human beings against diseases, saving the lives of millions of people around the world every year. Vaccines are administered either to prevent occurrence of a disease, called preventive or prophylactic vaccines, or after a disease occurs which are referred to as therapeutic vaccines. Prophylactic vaccines represent the dominant segment of the global vaccines market. Factors such as increasing incidence and prevalence of various diseases, growing costs of disease treatment, increasing focus on inclusion of vaccines in national immunization programs and growing support from non-governmental institutions are creating demand for vaccines. The pharmaceutical industry is responding with the launch of new and more effective vaccines for previously untargeted diseases supported by growing investments in the development of new generation vaccines and advancements in vaccine technologies. The growth in the market is driven by novel vaccines, such as Prevnar 13 and Gardasil 9, which offer protection against more serogroups of diseases. Extended protection offered by these vaccines is driving their acceptance among patient and physician population worldwide. Pneumococcal vaccines witnessed sizable growth in recent years, driven by the surging sales of Pfizer’s Prevnar 13. Despite the opportunities for growth, the market will be challenged by several factors such as supply and accessibility issues primarily in the emerging markets, higher and rising prices of certain new vaccines which prevent developing countries from including them in immunization programs, safety issues and stringent regulatory procedures, and vaccines shortages for certain diseases.

As stated by the new market research report on Prophylactic Human Vaccines, the United States represents the largest market worldwide supported by a more aware and educated population and high vaccination coverage rates. Most multinational companies engaged in vaccine production are based in the country. Emerging countries represent large untapped markets with tremendous opportunities for future expansion and growth. With large population base and relatively high proportion of young children and teen population, emerging markets including China and India represent the fastest growing markets in Asia-Pacific. The region ranks as the fastest growing market with a CAGR of 10.6% through the analysis period. Pediatric prophylactic vaccines represent the largest segment in the global market, while adult prophylactic vaccines are expected to spearhead growth through the review period.

Major players covered in the report include ALK – Abelló A/S, Altimmune, Inc., Bavarian Nordic A/S, BiondVax Pharmaceuticals Ltd., Bharat Biotech International Limited, GlaxoSmithKline Plc., Hualan Biological Engineering Inc., Janssen Pharmaceuticals, Inc., MedImmune, Merck & Company, Inc., Pfizer Inc., Sanofi Pasteur SA, Serum Institute of India Pvt. Ltd., Shanghai BravoBio Co., Ltd., Seqirus, and Takeda Pharmaceutical Company Limited among others.

The research report titled “Prophylactic Human Vaccines: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Biopesticides in terms of US$ for all major geographic markets such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe) Asia-Pacific (China, India and Rest of Asia-Pacific), Latin America (Brazil and Rest of Latin America) and Rest of World. Product segments analyzed in the report include Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines. 

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.